⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 29, 2026Journal of Dermatological TreatmentOpen Access

Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial

Chaoying Gu Aijun Chen Huibin Yin Suwei Tang Jinhua Xu

View Full Paper

Ask AI

Bookmark

Share

Key Points

Assess the efficacy and tolerability of ivarmacitinib in treating moderate to severe atopic dermatitis based on baseline patient characteristics.
Post-hoc analysis of a phase 3 clinical trial
Evaluated patient characteristics stratification
Measured efficacy and tolerability outcomes
Ivarmacitinib demonstrated notable efficacy in moderate to severe atopic dermatitis
Good tolerability observed across diverse patient characteristics

Implication

Post-hoc analysis reports ivarmacitinib efficacy in treating atopic dermatitis, indicating diverse patient impacts.

Abstract

Ivarmacitinib demonstrated efficacy and good tolerability in treating moderate to severe AD with diverse patient characteristics.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gu et al. (2026) studied this question.

synapsesocial.com/papers/6980fecbc1c9540dea811221 https://doi.org/10.1080/09546634.2025.2596524

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial2025 · 1 citations
2Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial2025
3Ivarmacitinib ointment for the treatment of adults with mild-to-moderate atopic dermatitis: phase 3 part of a randomized, double-blind, placebo-controlled, phase 2/3 clinical trial2025 · 3 citations
4Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a <i>post hoc</i> analysis of a phase-III trialHuman Clinical Trial · 2026
5P081 A highly selective Janus kinase 1 inhibitor, ivarmacitinib ointment, for the treatment of atopic dermatitis: results from a phase II study2024 · 2 citations

More related papers

52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial2026
Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial2025
Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III trial2025

More from Journal of Dermatological Treatment

Balancing safety and efficacy in photodynamic therapy for facial port-wine stains in children aged 2-7 years: a prospective controlled study of light-intensity optimizationFri,
5-Aminolevulinic acid-based photodynamic therapy used as a long-term management approach for refractory lichen sclerosusWed,